INF39

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

INF39

CAS No. : 866028-26-4

MCE 国际站：INF39

产品活性：INF39 是不可逆的，没有细胞毒性的NLRP3 抑制剂。

研究领域：Immunology/Inflammation

作用靶点：NOD-like Receptor (NLR)

In Vitro: INF39 is able to significantly inhibit ATP- and nigericin-induced IL-1β release at 10 μM. INF39 reduces caspase-1 activation and pyroptosis in the macrophages. INF39 can block not only NLRP3 activation but also the NF-κB pathway. INF39 potentially reacts with Cys-SH residues in the active site of cysteine protease caspase-1, but does not directly target caspase-1 activity. INF39 is able to reduce the steady state (or basal) BRET signal of NLRP3 without affecting the viability of cells, meaning that it can interfere with the basal NLRP3 conformation. INF39 does not block the initial conformational changes suffered by NLRP3 upon sensing the decrease of intracellular K⁺; however, it affects a second step of NLRP3 conformational change that could be related with the ATPase activity of the receptor and be independent of the decrease of intracellular K⁺. INF39 reaches the intestinal epithelium without undergoing chemical modifications. After absorption into epithelial cells, it is likely to act locally at the mucosal epithelial level.

In Vivo: Oral administration of INF39 reduces systemic and colonic inflammation in rats treated with 2,4- dinitrobenzenesulfonic acid. Significant increments of body weight are observed in inflamed rats under treatment with INF39 (12.5, 25, and 50 mg/ kg). Treatment with DNBS results in a significant increment of spleen weight (+39.3%). Such an increase is significantly reduced by administration of INF39 (+2.2, +4.3 and +4.8% at 12.5, 25, 50 mg/kg, respectively). The inhibition of NLRP3 inflammasome complex with INF39 dose-dependently attenuates the decrease in colonic length (−19, −13 and −8% at 12.5, 25, 50 mg/kg, respectively). Rats treated with INF39 displays a significant reduction of macroscopic damage score (4.7 at 12.5 mg/kg, 3.1 at 25 mg/kg, and 2.8 at 50 mg/kg). Oral administration of INF39 reduces colonic myeloperoxidase, IL-1β, and TNF Levels in DNBS-treated rats.

相关产品：Covalent Screening Library Plus  |  Bioactive Compound Library Plus  |  Immunology/Inflammation Compound Library  |  NF-κB Signaling Compound Library  |  Covalent Screening Library  |  Antioxidant Compound Library  |  Oxygen Sensing Compound Library  |  Pyroptosis Compound Library  |  Antidepressant Compound Library  |  Membrane Protein-targeted Compound Library  |  Membrane Receptor-targeted Compound Library  |  Autoimmune Disease Compound Library  |  MCC950 sodium  |  Nigericin sodium salt  |  QS-21  |  CY-09  |  Muramyl dipeptide  |  Trimethylamine N-oxide  |  Dapansutrile  |  GSK717  |  Stavudine  |  Muscone  |  NLRP3/AIM2-IN-3  |  Selnoflast  |  BMS-986299  |  NOD-IN-1  |  Troxerutin  |  Echinatin  |  Licochalcone B  |  Mifamurtide  |  Nodinitib-1  |  Ruscogenin  |  Emlenoflast sodium  |  Arglabin  |  CORM-3  |  JC2-11  |  4'-Methoxyresveratrol  |  YQ128  |  GDC-2394  |  NLRP3-IN-2

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds